Close Menu

NEW YORK (GenomeWeb News) – Massachusetts General Hospital, the Broad Institute, and Amgen are collaborating to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease, the partners said today.

While scientists have identified more than 150 regions of the genome that place a person at risk for developing IBD, treatments that make use of this knowledge are "urgently needed," the partners said, noting that recently developed IBD drugs are not always effective and can cause significant side effects in some patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.